Clinical Trials

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03856216 2026-04-15

Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell Transplantation

15 enrolled 11 charts

Burkitt Lymphoma, Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01679119 2026-04-07

INCA

Phase 2 Completed

129 enrolled 7 charts

Lymphoma, Large B-Cell, Diffuse

NCT03150693 2026-04-07

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

Phase 3 Suspended

310 enrolled

Phase 2 Active not recruiting

Burkitt Lymphoma

NCT05303792 2026-04-07

Testing the Combination of Inotuzumab Ozogamicin and Lower Dose Chemotherapy Compared to Usual Chemotherapy for Adults With B-Cell Acute Lymphoblastic Leukemia or B-Cell Lymphoblastic Lymphoma

68 enrolled

Burkitt Lymphoma, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

NCT04747912 2026-03-30

Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO)

Phase 2 Suspended

25 enrolled

Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06985485 2026-03-24

Full-Course Immunotherapy Consolidation for Unfit or Fit B-ALL Who Decline Chemotherapy

26 enrolled

Phase 3 Not yet recruiting

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07476729 2026-03-17

International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)

750 enrolled

Burkitt Lymphoma

NCT06863259 2026-02-18

Study of Inotuzumab Ozogamicin, Venetoclax, and Dexamethasone for Relapsed B-cell ALL

Phase 1 Recruiting

28 enrolled

Phase 2 Active not recruiting

Burkitt Lymphoma, Recurrence

NCT03441061 2026-02-17

Inotuzumab Ozogamicin in Treating Patients With B-cell Acute Lymphocytic Leukemia With Positive Minimal Residual Disease

40 enrolled

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06287229 2026-02-17

Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients With Relapsed/Refractory (R/R) and Newly Diagnosed B-cell Acute Lymphocytic Leukemia (ALL) Post Cytoreduction With Mini-HCVD-inotuzumab-blinatumomab/HCVAD-inotuzumab-blinatumomab

Phase 1/2 Recruiting

40 enrolled

Burkitt Lymphoma, Recurrence

NCT03913559 2026-02-12

Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia

5 enrolled

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06533748 2026-02-12

Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma

128 enrolled

Phase 1 Active not recruiting

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05016947 2026-01-29

Venetoclax Plus Inotuzumab for B-ALL

23 enrolled

Burkitt Lymphoma, Lymphoma, B-Cell

NCT01371630 2025-12-18

Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia

Phase 1/2 Recruiting

276 enrolled

Burkitt Lymphoma

NCT06387121 2025-12-17

Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALL

53 enrolled

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07238907 2025-11-25

A Multi-center Retrospective Study of INO Treating B-ALL

Active not recruiting

102 enrolled

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02877303 2025-11-06

Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia

80 enrolled

Burkitt Lymphoma, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

NCT05645718 2025-10-07

Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia

Other hematologic neoplasm

27 enrolled

Leukemia

NCT03104491 2025-06-05

Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia

Phase 1/2 Recruiting

44 enrolled

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06554626 2024-08-15

Blinatumomab Plus Venetoclax Sequenced With Inotuzumab Ozogamicin in Treating B-ALL

20 enrolled

Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

NCT06427330 2024-07-30

Phase II Study of Post-Transplant Low-Dose Inotuzumab Ozogamicin to Prevent Relapse of Acute Lymphoblastic Leukemia

21 enrolled

Other hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01664910 2024-07-23

CMC-544 and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies

Phase 1/2 Completed

27 enrolled 12 charts

Hematologic Neoplasms

NCT01134575 2024-07-16

CMC-544 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL)

Phase 2 Completed

90 enrolled 10 charts

Burkitt Lymphoma, Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03488225 2024-07-16

Combination Chemotherapy and Inotuzumab Ozogamicin in Treating Patients With B Acute Lymphoblastic Leukemia

4 enrolled 11 charts

Burkitt Lymphoma

NCT06087419 2023-11-02

A Prospective Clinical Study of Bridging alloHSCT After Treatment With Obinutuzumab in Combination With Chidamide and Venetoclax in RR Ph-ALL and B-cell Lymphoma Patients

Phase 1/2 Unknown

42 enrolled

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03249870 2023-09-06

EWALL-INO

Phase 2 Unknown

130 enrolled

Phase 1 Active not recruiting

Philadelphia Chromosome, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03962465 2023-08-22

ALL-001

36 enrolled

MyeloidOther hematologic neoplasm

Burkitt Lymphoma

NCT02311998 2023-07-17

Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive PC Positive ALL and CML

Phase 1/2 Completed

22 enrolled 14 charts

Blast Crisis, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT03991884 2023-07-06

Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia

Phase 1 Completed

24 enrolled

Burkitt Lymphoma, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

NCT03460522 2022-11-02

Inotuzumab Ozogamicin and Conventional Chemotherapy In Patients Aged 56 Years and Older With ALL

Phase 2 Unknown

65 enrolled

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05603156 2022-11-02

A Study of Olverembatinib Combined With Inotuzumab Ozogamicin in the Treatment ph+ ALL With MRD Persistent Positive

Phase NA Unknown

46 enrolled

Tumor-Agnostic

Neoplasm, Residual

NCT03851081 2022-01-28

Inotuzumab Ozogamicin and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia

Phase 1/2 Withdrawn

Burkitt Lymphoma

NCT03610438 2022-01-04

ALL2418

Phase 2 Unknown

76 enrolled

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03094611 2021-04-12

Inotuzumab Ozogamicin in Treating Patients With Relapsed or Refractory CD22 Positive Acute Lymphoblastic Leukemia

4 enrolled 12 charts

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01562990 2016-05-23

Phase Ib/II Study of the Efficacy and Safety of the R-CMC544/R-GEMOX Combination in Diffuse Lage B-cell Lymphoma at First or Second Relapse

Phase 1/2 Completed

11 enrolled